Biotechnology
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

$1B

Market Cap • 4/3/2025

2014

(11 years)

Founded

2014

(11 years ago)

IPO

NASDAQ

Listing Exchange

Flag of US

Waltham

Headquarters • Massachusetts